Manuel F Balandrin
Hearing Aid Provider in Sandy, UT
License number
Utah 150573-8914
Issued Date
Jan 4, 1993
Expiration Date
May 31, 2007
Category
xControlled Substance Handler
Type
Controlled Substance Handler Individual
Address
Address
Sandy, UT
Personal information
See more information about Manuel F Balandrin at radaris.comName
Address
Phone
9184 S Winter Wren Dr, Sandy, UT 84093
9184 Winter Wren Dr, Sandy, UT 84093
Holladay, UT
9184 Winter Wren Dr, Sandy, UT 84093
Professional information
See more information about Manuel F Balandrin at trustoria.com
Inorganic Ion Receptor Active Compounds
Inorganic Ion Receptor Active Compounds
US Patent:
6342532, Jan 29, 2002
Filed:
Oct 6, 1999
Appl. No.:
09/415179
Inventors:
Scott T. Moe - Salt Lake City UT
Bradford C. Van Wagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Richard Trovato - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. Van Wagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Richard Trovato - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31137
US Classification:
514648, 514654, 514452, 514466, 564319, 564378, 564380, 564383, 549362, 549440
Abstract:
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
US Patent:
6306912, Oct 23, 2001
Filed:
Jun 7, 1995
Appl. No.:
8/483294
Inventors:
Alan L. Mueller - Salt Lake City UT
Bradford C. VanWagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Bradford C. VanWagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31135
US Classification:
514648
Abstract:
Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
US Patent:
6017965, Jan 25, 2000
Filed:
Dec 11, 1996
Appl. No.:
8/763480
Inventors:
Alan L. Mueller - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. VanWagenen - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT
Daryl L. Smith - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. VanWagenen - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT
Daryl L. Smith - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31135, C07C21762
US Classification:
514649
Abstract:
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
Method Of Screening Calcium Receptor-Active Molecules
Method Of Screening Calcium Receptor-Active Molecules
US Patent:
5858684, Jan 12, 1999
Filed:
Jun 7, 1995
Appl. No.:
8/480751
Inventors:
Edward F. Nemeth - Salt Lake City UT
Edward M. Brown - Milton MA
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Bradford C. Van Wagenen - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. Del Mar - Salt Lake City UT
Edward M. Brown - Milton MA
Steven C. Hebert - Wellesley MA
James E. Garrett - Salt Lake City UT
Bradford C. Van Wagenen - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. Del Mar - Salt Lake City UT
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
NPS Pharmaceuticals, Inc. - Salt Lake City UT
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
C12Q 168
US Classification:
435 72
Abstract:
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca. sup. 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Calcium Receptor-Active Molecules
Calcium Receptor-Active Molecules
US Patent:
6001884, Dec 14, 1999
Filed:
Jun 6, 1995
Appl. No.:
8/469204
Inventors:
Edward F. Nemeth - Salt Lake City UT
Bradford C. Van Wagenen - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. Delmar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Bradford C. Van Wagenen - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. Delmar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A01N 3500
US Classification:
514699
Abstract:
The present invention features molecules which can modulate one or activities of an inorganic ion receptor. Preferably, the molecule can mimic or block the effect of extracellular Ca. sup. 2+ on a calcium receptor. The preferred use of such molecules is to treat diseases or disorders by altering inorganic ion receptor activity, preferably calcium receptor activity.
Methods And Compounds For Treating Depression And Other Disorders
Methods And Compounds For Treating Depression And Other Disorders
US Patent:
2004003, Feb 26, 2004
Filed:
Nov 21, 2001
Appl. No.:
09/990405
Inventors:
Alan Mueller - Salt Lake City UT, US
Scott Moe - Salt Lake City UT, US
Manuel Balandrin - Sandy UT, US
Scott Moe - Salt Lake City UT, US
Manuel Balandrin - Sandy UT, US
Assignee:
NPS Pharmaceuticals, Inc.
International Classification:
A61K031/47, A61K031/44, A61K031/381, A61K031/341, A61K031/137
US Classification:
514/307000, 514/314000, 514/357000, 514/438000, 514/471000, 514/546000, 514/649000
Abstract:
The present invention features compounds active at both the serotonin reuptake site and the N-methyl-D-aspartate (NMDA) receptor and the use of such compounds for treating different disorders. Compounds having activity at the serotonin reuptake site and the NMDA receptor (“multi-active compounds”) can be used to treat different types of disorders such as depression, obsessive-compulsive disorders (OCD), sleep, disorders, sexual dysfunction, and eating disorders. Preferably, the multi-active compounds are used to treat depression.
Calcium Receptor-Active Compounds
Calcium Receptor-Active Compounds
US Patent:
6211244, Apr 3, 2001
Filed:
Oct 23, 1995
Appl. No.:
8/546998
Inventors:
Bradford C. Van Wagenen - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. DelMar - Salt Lake City UT
Edward F. Nemeth - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. DelMar - Salt Lake City UT
Edward F. Nemeth - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31135, A01N 3302, C07C20948
US Classification:
514649
Abstract:
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca. sup. 2+ on a calcium receptor.
Calcium Receptor-Active Molecules
Calcium Receptor-Active Molecules
US Patent:
6313146, Nov 6, 2001
Filed:
Jun 7, 1995
Appl. No.:
8/484159
Inventors:
Bradford C. Van Wagenen - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. DelMar - Salt Lake City UT
Edward F. Nemeth - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Eric G. DelMar - Salt Lake City UT
Edward F. Nemeth - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A01N 4340, A61K 3144
US Classification:
514337
Abstract:
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca. sup. 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
Compounds Active At A Novel Site On Receptor-Operated Calcium Channels Useful For Treatment Of Neurological Disorders And Diseases
US Patent:
6051610, Apr 18, 2000
Filed:
Feb 18, 1999
Appl. No.:
9/252433
Inventors:
Alan L. Mueller - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. Van Wagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Bradford C. Van Wagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Robert M. Barmore - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31135, C07C21135
US Classification:
514628
Abstract:
Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
Quinazolinone Compounds As Calcilytics
Quinazolinone Compounds As Calcilytics
US Patent:
2006005, Mar 9, 2006
Filed:
Nov 4, 2003
Appl. No.:
10/531161
Inventors:
Irina Shcherbakova - Midvale UT, US
Manuel Balandrin - Sandy UT, US
John Fox - Salt Lake City UT, US
William Heaton - Salt Lake City UT, US
Rebecca Conklin - Park City UT, US
Damon Papac - Salt Lake City UT, US
Manuel Balandrin - Sandy UT, US
John Fox - Salt Lake City UT, US
William Heaton - Salt Lake City UT, US
Rebecca Conklin - Park City UT, US
Damon Papac - Salt Lake City UT, US
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/675, A61K 31/519, A61K 31/517, C07D 487/02, C07D 403/02, C07D 239/91
US Classification:
514081000, 514264100, 514266310, 514266210, 544244000, 544284000, 544286000, 544279000
Abstract:
Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Techniques which can be used to obtain calcilytic compounds and uses of calcilyitc compounds as calcium receptor antagonists are also disclosed.